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Thyrotoxicosis factitia induces
Takotsubo cardiomyopathy
in end-stage renal disease:
a pathogenetic hypothesis
To the Editor: We appreciate the report by Takemoto et al.1
onTakotsubo cardiomyopathy without an identiﬁable cause in a
patient undergoing long-term hemodialysis, which reﬂects the
great diversity of cardiovascular events in end-stage renal
disease patients. Although the etiology of Takotsubo cardio-
myopathy remains unclear in most cases, we would like to bring
to the readers’ attention an unusual cause of this stress
cardiomyopathy. A 31-year-old woman with Chinese herb
nephropathy and on continuous ambulatory peritoneal dialysis
for 16 months developed severe chest pain rapidly after taking
slimming pills containing triiodothyronine (128mg). Transient
left ventricular apical ballooning without evidence of coronary
artery abnormality was documented. In this patient, a burst of
enhanced, excessive sympathetic activity arising from thyrotox-
icosis factitia may have triggered a switch in intracellular signal
trafﬁcking in ventricular cardiomyocytes, from Gs protein to Gi
protein signaling via the b2-adrenergic receptors.
2 This strategy
counteracts the proapoptotic effect of excessive b1-adrenergic
Gs protein pathway activation and seems to act as a
physiological balance to prevent catecholamine-mediated
myocardial damage.3 In our patient, the ventricular function
and apical wall motion returned to normal 2 weeks later.
1. Takemoto F, Chihara N, Sawa N et al. Takotsubo cardiomyopathy in a
patient undergoing hemodialysis. Kidney Int 2009; 76: 467.
2. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the
b2-adrenergic receptor to different G proteins by protein kinase A. Nature
1997; 390: 88–91.
3. Chesley A, Lundberg MS, Asai T et al. The b2-adrenergic receptor delivers
an antiapoptotic signal to cardiac myocytes through Gi-dependent
coupling to phosphatidylinositol 30-kinase. Circ Res 2000; 87: 1172–1179.
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Antineutrophil cytoplasmic
autoantibody-associated vasculitis
on chronic dialysis
To the Editor: In a recent issue of Kidney International,
Lionaki et al.1 suggested that in antineutrophil cytoplasmic
autoantibody-associated vasculitis patients on dialysis, immu-
nosuppressants should be restricted to those with active
vasculitis. We quite agree with it, but some data are not
convincing enough to make such a conclusion. First, the
authors reported that in end-stage renal disease (ESRD)
patients, the infection rate was twice as high in patients
who were on immunosuppressants as in those who were
not on immunosuppressants. It is not a pertinent reason
for restricting immunosuppressants in ESRD patients, as
immunosuppressants would deﬁnitely increase the chances
of infection, regardless of ESRD or non-ESRD.2 Instead, the
authors should compare the frequency of infections between
ESRD and non-ESRD patients, both on immunosuppressants,
or demonstrate that in non-ESRD patients, the possibility of
infections being increased by immunosuppressants is much
less than twice. Moreover, other factors contributing to
infections should be adjusted. Second, the authors reported
that among ESRD patients, death rates were similar between
those with and those without active vasculitis. It is improper to
simply compare the ‘percentages’ without considering follow-
up durations. Instead, Cox-regression or, at least, Kaplan–Meier
analysis, should be used. Third, the authors reported that
infections and active vasculitis were the ﬁrst cause of death in
ESRD and non-ESRD patients, respectively. Such comparison
is an unbalance, as the former would mostly have already
received immunosuppressants and would thus be in remission,
while the latter are often in an active state. Instead, the authors
should compare the cause of death between ESRD and non-
ESRD patients, both in active and remission states. In addition,
the unavailability of the causes of death in many patients
makes such comparison unconvincing.
1. Lionaki S, Hogan SL, Jennette CE et al. The clinical course of ANCA small-
vessel vasculitis on chronic dialysis. Kidney Int 2009; 76: 644–651.
2. Chen M, Yu F, Zhang Y et al. Antineutrophil cytoplasmic autoantibody-
associated vasculitis in older patients. Medicine (Baltimore) 2008; 87:
203–209.
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The Authors Reply: We appreciate the opportunity to
respond to Chen and Zhao1 regarding our analysis of the
clinical course of antineutrophil cytoplasmic autoantibody
small vessel vasculitis2 on chronic dialysis. Drs Chen and
Zhao raise the concern that our results do not support the
statement that immunosuppressive therapy should be geared
only to patients with end-stage renal disease (ESRD) and
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active vasculitis, on the basis of three arguments: (1)
immunosuppressive medications increase the risk of infection
regardless of ESRD; (2) rates of death should take into
consideration duration of follow up; (3) comparison of causes
of death between ESRD and non-ESRD patients should take
into account the state of disease activity.
The goal of maintenance immunosuppressive therapy in
patients in remission is to decrease the risk of relapse.
Decisions regarding maintenance therapy must consider the
relative risks and beneﬁts of such therapy (risk/beneﬁt ratio).
Considering that the incidence of relapse was signiﬁcantly
lower after ESRD (0.08 episodes/person-year) compared with
the same patients before ESRD (0.2 episodes/person-year,
P¼ 0.0012), there is little potential beneﬁt of maintenance
immunosuppression after ESRD.
In describing the major causes of death in the ESRD
population, our goal was to highlight the frequency of infec-
tions, especially among immunosuppressed patients. Although
active vasculitis was a major cause of death in the ﬁrst month
after diagnosis, infection accounted for 50% of deaths beyond
then. Not surprisingly, infections were more frequent among
patients receiving immunosuppressants compared with those
who were not (1.94 vs 1.03 episodes/person-year, Po0.0001). In
aggregate, the high rate of serious infections coupled with the
low rate of relapse suggest that ESRD patients without active
vasculitis are more likely to suffer from severe or fatal infections
than relapsing disease. Therefore, the risk/beneﬁt ratio does not
support the routine use of maintenance immunosuppression
therapy in antineutrophil cytoplasmic autoantibody small vessel
vasculitis patients on chronic dialysis.
1. Chen M, Zhao M-H. Antineutrophil cytoplasmic autoantibody associated
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CRRT in series with extracorporeal
membrane oxygenation
in pediatric patients
To the Editor: We read with great interest the article by
Santiago et al.1 describing an institutional method of
performing continuous renal replacement therapy (CRRT),
using a dedicated machine in series with extracorporeal
membrane oxygenation (ECMO) in pediatric patients. We
previously described the same method with some important
differences,2 and subsequently evaluated the technical and
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Figure 1 | Schematic representation of continuous hemofiltration circuit in parallel and countercurrent to cardiopulmonary circuit.
CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation.
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